This phenomenon may be closely related to the difference in IDO expression level of HCC-tumors, explaining why several immune IDO inhibitor monotherapy studies show disillusionary results such as ECHO-301 (NCT02752074). This evidence concerns the gene IDO1 and hepatocellular carcinoma.